Drug intelligence / Profile preview

Aledex

Development stage: Unknown
Lead developer: Kane Biotech
Modality: Small Molecules

Overview

Aledex is a proprietary anti-biofilm and antimicrobial technology developed by Kane Biotech. It is a composition primarily consisting of antibiofilm protamine sulfate and antimicrobial chlorhexidine salt, and may include additional antimicrobials such as triclosan and benzalkonium chloride. This technology is designed to prevent and remove microbial biofilms, particularly in medical device coating applications to combat hospital-acquired infections. Kane Biotech also applies this technology in its animal health, wound care, and dermatology business units.

Brand names: Aledex

Targets

Chitin

Beyond the preview

Go deeper on Aledex.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aledex.

Explore the full profile